Alembic Pharma arm gets USFDA nod for Lidocaine and Prilocaine Cream
Lidocaine 2.5% and Prilocaine 2.5% cream is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.
Vadodara: Drugmaker, Alembic Pharmaceuticals Limited today announced that the company's wholly owned subsidiary, Aleor Dermaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) EMLA Cream, 2.5%/2.5%, of Teva Branded Pharmaceutical Products R&D, Inc.
Lidocaine 2.5% and Prilocaine 2.5% cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.
Read also: Alembic JV Aleor Dermaceuticals receives USFDA nod for Nystatin and Triamcinolone Acetonide Ointment
"Lidocaine 2.5% and Prilocaine 2.5% cream is not recommended in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies," the company stated in its recent release.
Lidocaine and Prilocaine Cream USP, 2.5%/2.5% has an estimated market size of US$29 million for twelve months ending Dec. 2021 according to IQVIA.
Alembic has received a cumulative total of 163 ANDA approvals (140 final approvals and 23 tentative approvals) from USFDA.
Read also: USFDA okays Alembic Pharma Dabigatran Etexilate Capsules
